Albireo 
Welcome,         Profile    Billing    Logout  
 11 Products   10 Diseases  11 Products   11 Trials   475 News 
18 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goofice (elobixibat) / Ipsen
R-LODD, NCT05165199: Elobixibat for Chronic Constipation Without Defecation Desire

Recruiting
4
40
Japan
Elobixibat 10mg
Yokohama City University
Chronic Constipation
09/22
03/23
NCT05703464: Elobixibat for Chronic Constipation Without Defecation Desire

Terminated
4
40
Japan
Elobixibat 10mg
International University of Health and Welfare
Chronic Constipation
03/23
03/23
TANK-27, NCT04784780: Long-term Elobixibat for Chronic Constipation

Recruiting
4
100
Japan
Elobixibat 10mg, AJG533 10 mg, Placebo, AJG533 placebo
Yokohama City University
Chronic Constipation
06/23
11/23
NCT05895877: Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation

Recruiting
3
351
RoW
Goofice®, Goofice® Placebo
Synmosa Biopharma Corp.
Constipation
09/23
09/23
NCT06436833: Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen

Recruiting
N/A
360
RoW
2-Liter polyethylene glycol plus elobixibat, 4-Liter polyethylene glycol
Rajavithi Hospital
Bowel Preparation Solution, Colonoscopy
11/24
12/24
cholestyramine (A3384) / Ipsen
2007-002863-28: Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria

Ongoing
4
21
Europe
Questran, Questran, Questran
Guy\'s & St Thomas\' NHS Foundation Trust
Erythropoietic protoporphyria (EPP)
 
 
NCT05014646: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Recruiting
2
56
US
Cholestyramine, Cholybar, Colestyramine, Duolite AP143 Resin, Questran, Questran Light, Leflunomide, Arava, SU101
City of Hope Medical Center, National Cancer Institute (NCI)
Smoldering Plasma Cell Myeloma
07/26
07/26
NCT06454383: Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Recruiting
1
19
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cholestyramine, Cholybar, Colestyramine, Duolite AP143 Resin, Questran, Questran Light, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Diagnostic Imaging, Medical Imaging, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Leflunomide, Arava, SU101, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
City of Hope Medical Center, National Cancer Institute (NCI)
Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
11/26
11/26
NCT05443425: Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

Recruiting
1
18
US
Cholestyramine, Cholybar, Colestyramine, Duolite AP143 Resin, Questran, Questran Light, Leflunomide, Arava, SU101, Steroid Therapy
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm
01/27
01/27
Bylvay (odevixibat) / Ipsen
ASSERT, NCT04674761 / 2020-004011-28: Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

Completed
3
52
Europe, Canada, US, RoW
Odevixibat, A4250, Placebo
Albireo
Alagille Syndrome
09/22
09/22
ASSERT-EXT, NCT05035030 / 2021-000996-36: Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

Recruiting
3
70
Europe, US, RoW
Odevixibat, A4250
Albireo, an Ipsen Company
Alagille Syndrome
04/26
04/26
PEDFIC 2, NCT03659916 / 2017-002325-38: Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

Active, not recruiting
3
116
Europe, Canada, US, RoW
A4250 (odevixibat)
Albireo, an Ipsen Company
Progressive Familial Intrahepatic Cholestasis
02/24
03/25
BOLD-EXT, NCT05426733: An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

Enrolling by invitation
3
180
Europe, Canada, US, RoW
Odevixibat, A4250
Albireo, an Ipsen Company
Biliary Atresia
07/28
08/28
BOLD, NCT04336722 / 2019-003807-37: Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE

Active, not recruiting
3
254
Europe, Canada, US, RoW
Odevixibat, Placebo
Albireo, an Ipsen Company
Biliary Atresia
06/26
07/26
2014-004070-42: Study to Demonstrate the Efficacy and Safety of A4250 in Patients withPrimary Biliary Cirrhosis and Cholestatic Pruritus

Ongoing
2
12
Europe
A4250,
Sahlgrenska Academy, Swedish Research Council
Primary biliary cirrhosis complicated by cholestatic pruritus.
 
 
NCT06258902: Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation

Recruiting
N/A
20
US
Ipsen
Pregnancy Related
09/31
09/32
NCT06850038: A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Recruiting
N/A
30
US
Ipsen
Alagille Syndrome
11/29
11/29
ritivixibat (IPN60250) / Ipsen
NCT05642468: Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

Active, not recruiting
2
18
Europe
Ritivixibat
Albireo, an Ipsen Company
Primary Sclerosing Cholangitis
07/25
07/25
insulin aspart 30 / HEC Pharm, Ipsen
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goofice (elobixibat) / Ipsen
R-LODD, NCT05165199: Elobixibat for Chronic Constipation Without Defecation Desire

Recruiting
4
40
Japan
Elobixibat 10mg
Yokohama City University
Chronic Constipation
09/22
03/23
NCT05703464: Elobixibat for Chronic Constipation Without Defecation Desire

Terminated
4
40
Japan
Elobixibat 10mg
International University of Health and Welfare
Chronic Constipation
03/23
03/23
TANK-27, NCT04784780: Long-term Elobixibat for Chronic Constipation

Recruiting
4
100
Japan
Elobixibat 10mg, AJG533 10 mg, Placebo, AJG533 placebo
Yokohama City University
Chronic Constipation
06/23
11/23
NCT05895877: Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation

Recruiting
3
351
RoW
Goofice®, Goofice® Placebo
Synmosa Biopharma Corp.
Constipation
09/23
09/23
NCT06436833: Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen

Recruiting
N/A
360
RoW
2-Liter polyethylene glycol plus elobixibat, 4-Liter polyethylene glycol
Rajavithi Hospital
Bowel Preparation Solution, Colonoscopy
11/24
12/24
cholestyramine (A3384) / Ipsen
2007-002863-28: Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria

Ongoing
4
21
Europe
Questran, Questran, Questran
Guy\'s & St Thomas\' NHS Foundation Trust
Erythropoietic protoporphyria (EPP)
 
 
NCT05014646: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Recruiting
2
56
US
Cholestyramine, Cholybar, Colestyramine, Duolite AP143 Resin, Questran, Questran Light, Leflunomide, Arava, SU101
City of Hope Medical Center, National Cancer Institute (NCI)
Smoldering Plasma Cell Myeloma
07/26
07/26
NCT06454383: Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Recruiting
1
19
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cholestyramine, Cholybar, Colestyramine, Duolite AP143 Resin, Questran, Questran Light, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Diagnostic Imaging, Medical Imaging, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Leflunomide, Arava, SU101, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
City of Hope Medical Center, National Cancer Institute (NCI)
Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
11/26
11/26
NCT05443425: Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

Recruiting
1
18
US
Cholestyramine, Cholybar, Colestyramine, Duolite AP143 Resin, Questran, Questran Light, Leflunomide, Arava, SU101, Steroid Therapy
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm
01/27
01/27
Bylvay (odevixibat) / Ipsen
ASSERT, NCT04674761 / 2020-004011-28: Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

Completed
3
52
Europe, Canada, US, RoW
Odevixibat, A4250, Placebo
Albireo
Alagille Syndrome
09/22
09/22
ASSERT-EXT, NCT05035030 / 2021-000996-36: Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

Recruiting
3
70
Europe, US, RoW
Odevixibat, A4250
Albireo, an Ipsen Company
Alagille Syndrome
04/26
04/26
PEDFIC 2, NCT03659916 / 2017-002325-38: Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

Active, not recruiting
3
116
Europe, Canada, US, RoW
A4250 (odevixibat)
Albireo, an Ipsen Company
Progressive Familial Intrahepatic Cholestasis
02/24
03/25
BOLD-EXT, NCT05426733: An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

Enrolling by invitation
3
180
Europe, Canada, US, RoW
Odevixibat, A4250
Albireo, an Ipsen Company
Biliary Atresia
07/28
08/28
BOLD, NCT04336722 / 2019-003807-37: Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE

Active, not recruiting
3
254
Europe, Canada, US, RoW
Odevixibat, Placebo
Albireo, an Ipsen Company
Biliary Atresia
06/26
07/26
2014-004070-42: Study to Demonstrate the Efficacy and Safety of A4250 in Patients withPrimary Biliary Cirrhosis and Cholestatic Pruritus

Ongoing
2
12
Europe
A4250,
Sahlgrenska Academy, Swedish Research Council
Primary biliary cirrhosis complicated by cholestatic pruritus.
 
 
NCT06258902: Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation

Recruiting
N/A
20
US
Ipsen
Pregnancy Related
09/31
09/32
NCT06850038: A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Recruiting
N/A
30
US
Ipsen
Alagille Syndrome
11/29
11/29
ritivixibat (IPN60250) / Ipsen
NCT05642468: Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

Active, not recruiting
2
18
Europe
Ritivixibat
Albireo, an Ipsen Company
Primary Sclerosing Cholangitis
07/25
07/25
insulin aspart 30 / HEC Pharm, Ipsen
No trials found

Download Options